EXONBIO

ExonBio is a private, early-stage biotech leveraging its patented SPIN® platform to accelerate and enhance monoclonal antibody discovery. The company appears to operate primarily as a service provider and platform developer, offering antibody discovery services and developing diagnostic antibodies for infectious diseases. While currently in a pre-revenue or early-revenue stage, its technology aims to address key bottlenecks in antibody development by isolating antigen-specific plasma cells with high affinity and native chain pairing.

Proprietary Single Plasma cell INterrogation (SPIN®) platform using microfluidics to isolate antigen-specific plasma cells for high-affinity, natively paired monoclonal antibody discovery.

ExonBio competes with established antibody discovery service providers using hybridoma, phage display, and single B cell technologies (e.g., AbCellera, GenScript, Creative Biolabs). In the IVD antibody space, it faces competition from large reagent suppliers (e.g., Thermo Fisher, Abcam) and specialized antibody developers.